Bergen, Norway, 23 April 2021; The Board of Directors in BerGenBio ASA (the “Company”) (OSE: BGBIO) have, to fulfil the Company’s obligations under the share option agreements and in accordance with the authorization granted by the general meeting on 19 March 2021, resolved to increase the Company’s share capital by NOK 6,617.30 by issuance of … Read more
Bergen, Norway, 21[st] April 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that BerGenBio CEO Mr. Richard Godfrey is presenting at the following virtual conference: Arctic Securities Biotech Webinar, April 22, 2021 Live presentation at 14.05hrs CET The presentation will … Read more
Dag 29 oppfølgning av siste rekrutterte pasient har nå skjedd i BGBC020 og ACCORD2-002 Innhentning av data pågår, og evaluering av effektdata er påbegynt Undersøkende analyser ønsker å definere undergrupper av pasienter med baseline markører som indikerer økt alvorlighetsgrad av sykdommen, med potensial for større nytte for pasienter Bemcentinib ble godt tolerert i begge studiene, … Read more
Day 29 follow-up of last patient enrolled has now occurred in BGBC020 and ACCORD2_002 Data receipt is ongoing and evaluation of efficacy data is underway Exploratory analyses are looking to define subsets of patients with baseline markers indicative of increased disease severity with the potential for greater benefit Bemcentinib was well tolerated throughout both studies, … Read more
Bergen, Norway, 30 March 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, announces that recruitment to the bemcentinib arm of the Phase two COVID-19 trial platform ACCORD, has been stopped today following review by the Scientific Advisory Committee. Due to the success of the vaccine roll out and public … Read more
Bergen, Norway – 19 Mars 2021: Annual General Meeting in BerGenBio ASA (OSE:BGBIO) was virtually held on on 19 March 2021 at 15:00 hours (CET). All proposals were resolved as presented in the notice convening the annual general meeting distributed on 25 February 2021, as further set out in the minutes from the annual general … Read more
Bergen, Norway – 15 March 2021: BerGenBio ASA (OSE:BGBIO) will be holding its Annual General Meeting (virtually) on 19 March 2021 at 15:00 hours (CET). The chairman of the board of directors of BerGenBio ASA (“BergenBio”), Sveinung Hole, has received proxies to vote at BerGenBio’s Annual General Meeting to be held on 19 March 2021 for a total of 7,570,836 shares, representing approx. 8.62% of the total share capital … Read more
Bergen, Norway, 12 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that it has completed enrolment into Cohort C1 of its Phase II study (BGBC008) of bemcentinib in combination with anti-PD-1 therapy Keytruda[®] (pembrolizumab) in refractory non-small cell lung cancer (NSCLC) patients. … Read more
Bergen, Norway, 8 March 2021 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, is pleased to announce that Richard Godfrey, CEO of BerGenBio, will be presenting at the following virtual conferences: H.C. Wainwright Global Life Sciences Conference Date: 9-10 March 2021Presentation available during the … Read more
Bergen, Norway, 6[th] March 2021 - BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical need, today delivered a Science Spotlight oral presentation on preclinical COVID-19 data at the annual Conference on Retroviruses and Opportunistic Infections (CROI), taking place from 6-10 March 2021. The presentation was led by BerGenBio’s scientific collaborator, Professor Wendy … Read more
soug@oncoinvent.com
Oystein Soug has over 15 years of experience in biotechnology, holding several management positions. Most recently, Mr. Soug was CEO of Arxx Therapeutics, where he led the company to initiate the clinical programme and was responsible for the merger with Dutch pharma company Oxitope Pharma to create Calluna Pharma. Prior to Arxx, he served as CFO and then CEO of Targovax, an Oslo listed biotechnology company, which went public during Mr. Soug’s tenure. Mr. Soug started his career in biotech as CFO of Oslo-listed radiopharmaceutical company Algeta. During this period, the company conducted a successful phase 3 trial, launched its radium-223 based prostate cancer drug Xofigo® and out-licensed the drug. Mr. Soug co-led the sale of the company to Bayer in 2014.
Mr. Soug holds an MSc in Economics and
Financial Markets from Universität St. Gallen in Switzerland in 1997
mansson@oncoinvent.com
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.